The current paper aims to provide an overview of methamphetamine in its historical context, integrated with a current understanding derived from animal studies and clinical experience.
Conclusion:
Despite over a century of clinical experience, methamphetamine remains a troublesome substance. There remains an urgent need at multiple levels from various sectors to combat this ongoing problem, and psychiatry has an essential role in this endeavour.
AnglinMDBurkeCPerrochetB. History of the methamphetamine problem. J Psychoactive Drugs2000; 32: 137–141.
2.
RasmussenN. America’s first amphetamine epidemic 1929–1971: a quantitative and qualitative retrospective with implications for the present. Am J Public Health2008; 98: 974–985.
3.
PanenkaWJProcyshynRMLecomteT. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend2013; 129: 167–179.
4.
MonroeRRDrellHJ. Oral use of stimulants obtained from inhalers. J Am Med Assoc1947; 135: 909–915.
5.
SaraGBurgessPHarrisM. Stimulant use disorders: characteristics and comorbidity in an Australian population sample. Aust N Z J Psychiatry2012; 46: 1173–1181.
6.
DegenhardtLSaraGMcKetinR. Crystalline methamphetamine use and methamphetamine-related harms in Australia. Drug Alcohol Rev. 2017; 36: 160–170.
7.
LaiFYO’BrienJThaiPK. Trends in methamphetamine residues in wastewater in metropolitan and regional cities in south-east Queensland, 2009–2015. Med J Aust2016; 204: 151–152.
8.
TscharkeBJChenCGerberJP. Trends in stimulant use in Australia: a comparison of wastewater analysis and population surveys. Sci Total Environ2015; 536: 331–337.
9.
DegenhardtLLarneySChanG. Estimating the number of regular and dependent methamphetamine users in Australia, 2002–2014. Med J Aust2016; 204: 153.
10.
SaraGBurgessPMalhiG. Amphetamine availability and admissions for psychosis in New South Wales, 2001–2009. Aust N Z J Psychiatry2011; 45: 317–324.
11.
SaraGEBurgessPMMalhiGS. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. J Clin Psychiatry2014; 75: 349–356.
12.
SaraGE. Drugs and psychosis … and now for some good news. Aust N Z J Psychiatry2014; 48: 484–485.
13.
HermensDFLubmanDIWardPB. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust2009; 190: S22–S25.
14.
VillemagneVYuanJWongDF. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci1998; 18: 419–427.
15.
MelegaWPJorgensenMJLacanG. Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. Neuropsychopharmacology2008; 33: 1441–1452.
16.
AkiyamaK. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence. Ann N Y Acad Sci2006; 1074: 125–134.
17.
UjikeHSatoM. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci2004; 1025: 279–287.
18.
FlaumMSchultzSK. When does amphetamine-induced psychosis become schizophrenia?Am J Psychiatry1996; 153: 812–815.
